Financing
Payment of Deferred Purchase Consideration
Biogen Payment of Deferred Purchase Consideration decreased by 91.9% to $11.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 769.2%, from $1.30M to $11.30M. Over 4 years (FY 2021 to FY 2025), Payment of Deferred Purchase Consideration shows an upward trend with a 87.2% CAGR.
Analysis
StatementCash Flow Statement
SectionFinancing
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
Metric ID:
isrg_payment_of_deferred_purchase_considerationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$31.90M | -$2.40M | $0.00 | $4.10M | $7.30M | -$5.50M | -$11.50M | $16.50M | -$16.80M | $2.20M | -$1.90M | $7.30M | -$1.30M | -$6.00M | $0.00 | $1.30M | $0.00 | $141.20M | $138.70M | $11.30M |
| QoQ Change | — | +92.5% | +100.0% | — | +78.0% | -175.3% | -109.1% | +243.5% | -201.8% | +113.1% | -186.4% | +484.2% | -117.8% | -361.5% | +100.0% | — | -100.0% | — | -1.8% | -91.9% |
| YoY Change | — | — | — | — | +122.9% | -129.2% | — | +302.4% | -330.1% | +140.0% | +83.5% | -55.8% | +92.3% | -372.7% | +100.0% | -82.2% | +100.0% | >999% | — | +769.2% |
Range-$31.90M – $141.20M
CAGR-19.6%
Avg YoY Growth+228.1%
Median YoY Growth+96.1%
Current Streak2 quarters decline
Payment of Deferred Purchase Consideration at Other Companies
Frequently Asked Questions
- What is Biogen's payment of deferred purchase consideration?
- Biogen (BIIB) reported payment of deferred purchase consideration of $11.30M in Q1 2026.
- How has Biogen's payment of deferred purchase consideration changed year-over-year?
- Biogen's payment of deferred purchase consideration increased by 769.2% year-over-year, from $1.30M to $11.30M.
- What is the long-term trend for Biogen's payment of deferred purchase consideration?
- Over 4 years (2021 to 2025), Biogen's payment of deferred purchase consideration has grown at a 87.2% compound annual growth rate (CAGR), from -$22.90M to $281.20M.